Modifi Biotech 2023 Investor Deck - DNA Repair Cancer

Modifi is a Yale-founded biotech company developing innovative cancer therapeutics that exploit DNA repair defects through direct DNA modification. The company's lead program targets HR-defective cancers with first-generation candidate selection planned for Q3 2023 and IND filing in H2 2024. The team includes prominent neuro-oncology researchers and is raising Series Seed 2 funding to support candidate declaration and IND-enabling studies.